Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells

Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients

Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.

Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better

Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.

A therapeutic revolution is happening.

Marseille Immunopole should allow us now to accelerate the development of therapeutic antibodies, the new drugs that are changing the course of cancer treatment.

“Projects like PIONeeR allow us to contribute to the understanding of resistance to immunotherapy while opening clinical research to patients in Corsica, who, until recently, had no choice other than to fly to Marseille or Paris for such opportunities.”

“Histopathology is critical to establish a diagnosis based on microscopic tissue examination, but is also of great importance to medical research protocols such as The PIONeeR Project.”

MI carries a strong voice for immunology research, freeing partners from their public or private sectors, breaking down disciplinary barriers and creating the essential conditions for acting together, quickly and sustainably

Education is also one of the strategic components of the Marseille Immunopole project.

“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”

Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.

MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate